Endocrine Abstracts

Introduction: Since the 1990’s cabergoline has become the treatment of choice in prolactinomas, allowing rapid and efficient hormonal and tumoral control in most cases. Evidence of cardiac valculopathy was demonstrated in patients treated by dopamine agonists for Parkinson disease, which led to curtailment of their use in this disease. Retrospective studies in hyperprolactinemia patients treated with cabergoline did not show such an effect, probably due to much lower dose...

Cabergoline (CAB) and other dopamine agonists are usually discontinued shortly after hyperprolactinemic patients become pregnant. Data on maternal and foetal exposure to CAB and on recurrence of hyperprolactinemia after pregnancy are still limited. The current survey study aimed at elucidating the safety of exposure to CAB during early pregnancy and the recurrence rate of hyperprolactinemia after pregnancy. Thus, 68 pregnancies in a cohort of 59 patients with hyperprolactinemi...

Women with acromegaly present often menstrual irregularity, anovularity and infertility. A direct role of GH and IGF1 excess on the hypothalamus–pituitary–gonadal axis, hyperprolactinemia and an impaired gonadotrophin secretion related to a tumor mass effect, or polycystic ovary syndrome have been suggested as possible mechanisms related to infertility. However, no systematic data are available on fertility in these patients. The aim of this retrospective study was t...